Übersetzung für "Kinderarzneimittel" in Englisch

Mr Liese raised the issue of paediatric medicines.

Only yesterday we voted measures to compensate for the cost of research for paediatric medicine.

That is why we now have to legislate on the question of medicinal products for paediatric use.

This regulation on paediatric medication is a concrete response to that expectation.

The Agency will receive entirely new responsibilities in the field of paediatric medicines.

This trend will be further strengthened as a consequence of the implementation of the paediatric legislation.

This regulation for children’s medicines is a concrete answer to their expectations.

Such RAPEX alerts are published on the Europa website, along with photographs of the dangerous products and details of the products’ name and brand.

In return for pharmaceutical companies carrying out mandatory clinical trials for drugs intended for use in children they will be given financial compensation.

In addition, the Commission adopted a proposal for a Regulation on paediatric medicines on 29 September 2004.

Pharmaceutical companies are often reluctant to invest in child-specific medicines, as the market for them is relatively small.

This core requirement has been included to ensure that medicines are developed for children based on their therapeutic needs.

Pharmaceutical companies are often reluc tant to invest in child-specific medicines as the market for them is relatively small.

The EMA published a 6-years annual report about the implementation of the Paediatric Regulation on the 1th of May 2013.

When raising a sensitive issue such as medication for children, however, we should ask ourselves an honest question, namely whether it is possible to claim beyond doubt that prescribing adult medication to children is more ethical than involving children in controlled studies that are subject to stringent legislative provisions.

It is therefore a good thing that European legislation should promote research into medicinal products that have been developed specifically for children and that we can thus put an end to this uncertainty.

I voted in favour of the Grossetête report on medicinal products for paediatric use, at second reading, because I feel that, in light of the specific nature of the child’s metabolism, medicines developed specifically for children should be promoted.

We have an interest in a strong Paediatric Committee, and what is more one which takes the lead.

I am also grateful to the Council and to the Austrian Presidency, which have taken note of the views of Parliament and given priority to the regulation of medicinal products for paediatric use.